BEDFORD, Ohio, April 11 /PRNewswire/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories Inc., has announced that it began shipping Mitoxantrone Injection USP on April 11, 2006. The product is AP rated and equivalent to Novantrone(R) by Serono Labs. Mitoxantrone is indicated as the initial chemotherapy for the treatment of pain related to advanced hormone-refractory prostate cancer. Also, in combination with other approved drug(s), it is indicated in the initial therapy of acute nonlymphocytic leukemia in adults.
“In our continuing effort to offer the most comprehensive line of oncology and oncology adjunct products in the multisource industry, Bedford Laboratories is once again very pleased to offer this very important product,” said David Gaugh, General Manager of Bedford Laboratories.
Bedford Laboratories will provide Mitoxantrone Injection USP, 2mg/mL, in three multi-dose presentations: 20mg/10mL, 25mg/12.5mL and 30 mg/15mL.
Prescribing information is available upon request from Bedford Laboratories’ professional services department, (800) 521-5169, or from the company’s web site, http://www.bedfordlabs.com.
Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 47 countries and approximately 37,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2005, Boehringer Ingelheim posted net sales of US $11.8 billion (9.5 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information please visit http://www.boehringer-ingelheim.com.
Bedford Laboratories
CONTACT: Natalie Haynes of Bedford Laboratories, 1-800-562-4797, ext. 3592
